~~<i id='79D95204B0'><strike id='79D95204B0'><tt id='79D95204B0'><pre id='79D95204B0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

fashion

author：Wikipedia 2025-10-01 23:06:04 - browse：4854

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Senate committee scrutinizes Medicare Advantage brokers

focus

Wikipedia

focus

leisure time

focus

RaDondaVaughtsitsinacourtroomaheadofhersentencinginNashville,Tenn.,onFriday,May13,2022.NicoleHester/

WSS

First Opinion Podcast: Long Covid needs a new approach

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Impact of Dobbs ruling felt at reproductive medicine meeting

President Biden's budget: Here's what you might have missed

STAT Readout Newsletter: Today's biggest biotech updates

STAT Summit: Biotech founders on deal

leisure time

fashion

focus

Medical leaders decry Supreme Court decision on affirmative action

FDA struggles to regulate food additives, sometimes for decades

Hepatitis C has a cure — but many Americans still lack access to it

Impact of Dobbs ruling felt at reproductive medicine meeting

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

2023 STAT Wunderkinds: get to know the winners

Dobbs anniversary: the lost opportunity of abortion as health care

WuXi out of biotech trade group, U.S. and China relations to blame

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Why health workers in Gaza are injured or die at high rates

Wikipedia

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Steward Health Care Massachusetts hospitals face fiscal disaster

Male and female sex labels in research insufficient, scientists say

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Hospital price transparency does save money, advocate argues

Why scientists need input from humanists on sensitive research

focus

leisure time

focus

focus